The administration of SCC244 has shown strong anticancer efficacy at well‐tolerated levels in xenografts of human tumor cell lines or NSCLC and HCC patient‐derived tumor tissue driven by MET abnormality. This evidence concerns the gene MET and non-small cell lung carcinoma.